DBV Technologies Announces Q3 2026 Financial Results and Business Developments

DBV Technologies has submitted a Biologics License Application (BLA) to the U.S. FDA for the VIASKIN® Peanut Patch for children aged 4-7, requesting priority review. The company has enhanced its commercial readiness for the product's potential U.S. launch. As of September 30, 2026, DBV reported cash and cash equivalents of $165.7 million, enough to fund operations into Q3 2027.

The financial results for Q3 2026 reveal a net loss of $64.5 million, with operating income dropping to $1.6 million. Research and Development expenses increased to $47.0 million due to intensified commercial readiness. Sales and Marketing expenditures rose significantly as the company continued U.S. launch preparations.

DBV remains committed to advancing its toddler program, with plans to submit the BLA for children aged 1-3 years in 2027. Regulatory discussions with the FDA aim for efficient review processes following recent submission activities.